e read with great interest the article by Alexander and colleagues (1) on the frequency of rpsA mutations in pyrazinamide-susceptible and resistant isolates with a wild-type pncA gene. In contrast to the report of Shi and colleagues (2), Alexander and colleagues could not find any rpsA mutations in pyrazinamide-resistant isolates and concluded that the analysis of the rpsA gene has no role in the diagnosis of pyrazinamide resistance.
Intrigued by their observations, we reexamined our sample of pyrazinamide-resistant isolates with wild-type pncA sequences, published previously in this journal (3) ( Table 1 ). This sample consisted of 5 isolates. rpsA gene sequencing was performed using the same methods as those of Alexander and colleagues (1) . Sequencing the rpsA gene revealed an A-to-G nucleotide change in codon 260 in one isolate, leading to an amino acid change from valine to isoleucine. No changes in the rpsA gene were seen in the other four isolates. So, in contrast to the findings of Alexander and colleagues, we were able to find a nonsynonymous rpsA mutation in pyrazinamide-resistant isolates with a wild-type pncA gene, albeit in a minority of cases.
Does this mean that rpsA sequencing could have a role in pyrazinamide resistance testing? To answer this question, we also reanalyzed our data on the accuracy of pncA gene sequencing in the diagnosis of pyrazinamide resistance (3). Incorporating rpsA gene sequencing in our proposed diagnostic algorithm (3) would increase sensitivity from 72% to 77%, indicating that rpsA gene sequencing had only a modest effect on sensitivity.
The finding of additional mutations correlated with pyrazinamide resistance, such as in the rpsA gene, is fascinating and offers important insights into the intracellular targets and behaviors of pyrazinamide. With the increasing possibilities for efficient determination of mutations, this could upgrade the reliability of testing resistance to this increasingly important antituberculosis drug (4). However, we agree with Alexander and colleagues that the role of rpsA gene sequencing itself in the diagnosis of pyrazinamide resistance is modest at best. 
